# BPC-157 TB-500 References: The Cited Literature Behind the Wolverine Blend

> BPC-157 TB-500 references: the full cited literature behind the Wolverine blend — Staresinic 2003, Hsieh 2017, Irobi 2004, the recent reviews, and the FDA 503A sources, with PMIDs and DOIs.

Every numbered claim on this site resolves here. Constituent studies, recent reviews, and the FDA 503A access record — with PMIDs, DOIs and source URLs.

## How to read this list

The BPC-157 TB-500 references below are the complete cited basis for this site. Citations 1-5 are the constituent studies — the established single-compound mechanisms and the flagship tendon finding. Citations 6-8 are the recent systematic and narrative reviews that bound the evidence honestly. Citation 9 consolidates the dosing-context and human-data record. Citations 10-12 are the FDA sources for the regulatory and access page. No claim on this site is made without a numbered source here; where a claim is blend-level, the citation establishes that the controlled evidence does not exist. The full set is gathered as the [Wolverine blend references](/references) index.

## References

[1] Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. https://pubmed.ncbi.nlm.nih.gov/14554208/
[2] Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. https://pubmed.ncbi.nlm.nih.gov/27847966/
[3] Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004. https://pubmed.ncbi.nlm.nih.gov/15329672/
[4] Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012. https://pubmed.ncbi.nlm.nih.gov/22074294/
[5] Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012. https://pubmed.ncbi.nlm.nih.gov/22962027/
[6] Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. https://pubmed.ncbi.nlm.nih.gov/40756949/
[7] Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. https://pubmed.ncbi.nlm.nih.gov/40789979/
[8] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. https://pubmed.ncbi.nlm.nih.gov/41966639/
[9] Dosing-context and human-data synthesis for BPC-157 and TB-500 (constituent rodent dose ranges, the rat/dog BPC-157 elimination half-life of under 30 minutes, full-length Thymosin Beta-4 human Phase 1 pharmacokinetics, and the absence of any controlled BPC-157 + TB-500 combination trial), compiled from the studies cited at refs 1-8 and the corpus research record. https://pubmed.ncbi.nlm.nih.gov/40756949/
[10] U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. FDA Advisory Committee Calendar. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
[11] U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (Category 2 entries for BPC-157 and for 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500'; entries effective September 29, 2023). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
[12] U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 1 / Category 2 definitions; the 503A/503B framework; the January 7, 2025 revised interim policy). https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act

---

Two peptides held on one status board — BPC-157 and TB-500 graded against their own studies, the combination row left reading NO-HUMAN-DATA and the 503A status posted as it stands, with no clinic behind the board and nothing here prescribed or sold.